MTOR and cancer: The observation that that 17% of breast cancer tumor xenografts develop DDIT4 amplifications in comparison to a low frequency in primary tumors (Figure S1) suggests strongly that DDIT4 activity is important for cancer progression; in the other hand, Bhola et al. 19 described the enrichment of cancer stem cells in TNBC cell lines after treatment with PIK3/mTOR or TORC1/2 inhibitors, it correlates with the worse outcome seen in patients overexpressing DDIT4, mainly in patients with acute myeloid leukemia19.